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Aspartame Cancer 
Risks Revisited
Prenatal Exposure May Be Greatest Concern
Aspartame is an artificial sweetener used in more than 6,000 diet
products, beverages, and pharmaceuticals. In March 2006, EHP
published the first compelling experimental evidence for the car-
cinogenic effects of aspartame at a dose level within range of
human daily intake [EHP 114:379–385; Soffritti et al.]. A second
animal study by the same research team now indicates that the car-
cinogenic effects of aspartame are magnified when exposure begins
during fetal life [EHP 115:1293–1297; Soffritti et al.].
The first study involved a much larger sample size than had
been used in previous experiments. It showed a dose-related
increase in the incidence of various malignant tumors in female rats
fed aspartame from 8 weeks of age until natural death. The experi-
ment was impressive for its long observation period and compre-
hensive assessment of aspartame’s carcinogenic potential.
Nevertheless, as the researchers acknowledged, the study did not
take into account prenatal or perinatal exposures. 
In the new study, the investigators added aspartame to the standard
diets of male and female Sprague-Dawley rats from the twelfth day of
fetal life until natural death. Rats were fed in groups of 70 to 95 each at
aspartame concentrations of 2,000, 400, and 0 ppm—approximately
equivalent to a daily intake of 100, 20, or 0 mg/kg body weight. The
current limits for acceptable daily intake are set at 50 mg/kg body
weight in the United States and 40 mg/kg body weight in Europe.
The researchers report that rats fed at the 400 ppm level
showed nonsignificant increases in malignancies. For animals fed
at the 2,000 ppm level, there was a significant increase in the inci-
dence of lymphomas/leukemias and malignant mammary tumors.
Furthermore, compared with the team’s earlier study in which ani-
mals were dosed postnatally only, the incidence of animals bearing
lymphomas/leukemias increased from 18.7% to 31.4%. The 2,000
ppm level corresponds to an assumed daily intake of 100 mg/kg
body weight—approximately the equivalent of a 45-pound child
drinking 5 cans of diet soda or a 150-pound adult consuming
14 packets of sweetener per day.
Although recent epidemiologic studies have not found an asso-
ciation between aspartame and human cancers, those studies were
not designed to measure cancer risks associated with fetal exposures.
The public health implications of the new findings are consider-
able. Currently, more than 200 million people regularly consume
aspartame, and children and women of childbearing age (which
presumably includes many who are pregnant and breastfeeding) are
among the major consumers. If the U.S. FDA were to conclude
that exposure to aspartame causes cancer in rodents, the agency
would be required by law to revoke its approval for the popular
sweetener. –M. Nathaniel Mead
The Best Rodent for the Job
NTP Workshop Compares Models
Researchers have long used rats and mice to understand the poten-
tial links between environmental exposures and incidences of
breast, ovarian, testicular, and prostate tumors. Concern exists,
however, that rodent models are not optimal for detecting car-
cinogens that act through the hormone system. To address this
concern, the National Toxicology Program (NTP) organized a
workshop in May 2006 to evaluate the utility of current two-
year rodent bioassays to adequately evaluate these hormon-
ally mediated tumors and the relevance of the findings to
humans [EHP 115:1351–1356; Thayer and Foster].
The workshop, part of a series of events aimed at
evaluating and refining the NTP’s testing program,
included representatives from academia, industry,
government, and nonprofit
groups, as well as a panel of
invited experts in endocrinolo-
gy, cancer biology, reproductive
toxicology, statistics, and other
fields. Workshop participants
were concerned that many hor-
monally mediated tumors, such
as those in the testes and
breasts, are initiated in fetal or
early neonatal life, yet these
periods of exposure are not
covered in the NTP’s standard
cancer bioassay. In response to
this concern, the NTP has com-
mitted to routinely include
perinatal exposures in these
studies unless there is a specific
justification not to do so.
Furthermore, some rat and mouse strains used in testing
either do not develop certain tumors or have a high incidence of
spontaneous tumors. For example, the F344/N rat typically
used by the NTP has high background incidences of testicular
Leydig cell tumors and mononuclear cell leukemia, along with
unresolved issues about declining fertility, sporadic seizures, and
chylothorax (accumulation of lymphatic fluid in the pleural cav-
ity, which can result from lymphoma). By press time, in
response to this and other workshop findings, the NTP
had selected the Wistar Han as its standard rat strain
for cancer and noncancer end points, although
other strains will be used when appropriate.
Although rodent models are considered to
have certain deficiencies and can be improved,
they are considered valuable nonetheless.
Rodent models for prostate and ovarian tumors
are the most problematic
for understanding human
disease because of signifi-
cant interspecies differ-
ences in anatomy and
tumor prevalence. Partic-
ipants in the workshop
recommended using alter-
native models, such as
genetically engineered
models and in vitro sys-
tems, to address some of
these deficiencies. They
also recommended more
in-depth investigation of
how noncancerous changes
observed in rodents might
be relevant to human
diseases. –Julia R. BarrettT
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Baring Bone’s Secrets
Understanding How Lead Exposure Affects
Skeletal Development
Among lead’s well-known developmental health effects is stunting of
skeletal growth in children. Moreover, lead is known to delay fracture
healing and may contribute to osteoporosis. Yet the exact mechanism
by which lead affects normal cellular functions in bone and cartilage
is poorly understood. A new study reports in vitro and in vivo effects
of lead on cell signaling during differentiation of embryonic stem
cells destined to form bone and cartilage [EHP 115:1276–1282;
Zucsik et al]. 
Chondrogenesis is the process by which a mesenchymal cell—a
type of stem cell already assigned to become connective tissue or
blood cells—turns into a cartilage cell, or chondrocyte. As chondro-
cytes mature, they differentiate further into bone and more special-
ized types of cartilage. Because the early embryo makes a cartilage
model of the skull, spine, and limbs, chondrogenesis is vital to full
skeletal development.
The authors exposed mouse mesenchymal cells to lead in vitro
and observed signaling changes in several proteins active in chon-
drogenesis: transforming growth factor-beta (TGF-β), bone mor-
phogenetic protein (BMP), activating protein 1 (AP-1), and nuclear
factor kappa B (NFκB). They also implanted mesenchymal cells
expressing BMP-2 in the thighs of living mice. Before implantation,
the mice had been exposed to lead through their drinking water. 
The in vitro experiment revealed several dose-dependent effects.
Lead stimulated chondrogenesis, influenced the regulation of chon-
drogenesis by BMP-2 and TGF-β, and induced expression of three
genes, also mediating the genes’ regulation by BMP-2 and TGF-β.
Similarly, in the in vivo experiment, lead was associated with a dose-
dependent induction of chondrogenesis at the implantation site.
Lead also inhibited
AP-1 signaling and
induced NFκB sig-
naling. However, on
the basis of previous
research on AP-1 and
NFκB with opposite
findings, the authors
do not believe either
of these pathways is
responsible for the
heightened chondro-
genesis observed in
the current study.
TGF-β proteins
are mediated by mem-
bers of the Smad fami-
ly of transcription acti-
vators, and Smads also affect BMP signaling in some situations. In the
current study, lead inhibited BMP-2 Smad signaling while stimulating
the same in TGF-β. Lead’s inhibition of BMP-2 Smad signaling “repre-
sents the most robust signaling effect identified to date in a skeletal cell
type with regard to a candidate mechanism of [lead] toxicity,” the
authors state. At the same time, this finding implies that lead’s influence
on chondrogenesis operates independently of Smad signaling.
Given the importance of cartilage both in embryonic development
and in fracture repair later in life, stimulation of chondrogenesis seems
like a good thing; but if lead triggers the formation of too much cartilage
at the wrong time, or prevents its further maturation into bone, this
could explain lead’s crippling effects on the skeleton. And because mes-
enchymal cells may differentiate into a variety of cell types in addition to
cartilage, lead may also affect the development of other body systems.
–Valerie J. Brown
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In Search of a
Chlorpyrifos Antidote
Mechanisms Offer Clues
Treatments for acute organophosphate poisoning focus
on stopping the buildup of the neurotransmitter acetyl-
choline at nerve endings. But organophosphates also inter-
fere with neural cell development at much lower doses over a
window of time that extends from fetal to neonatal development.
This damage occurs through mechanisms that include direct inter-
actions with acetylcholine receptors, interference with intracellular
signaling cascades, and oxidative stress. Thus, any treatment aimed
at stopping these sorts of effects would need to address those differ-
ent mechanisms. Now researchers have advanced toward finding
such an antidote [EHP 115:1306–1313; Slotkin et al.]. 
The team tested four treatments on the neurodevelopmental
effects of the organophosphate pesticide chlorpyrifos. Using
pheochromocytoma (PC12) cells, a tumor cell line that displays the
major phases of neurodevelopment targeted by the pesticide, the
authors evaluated the different treatments in terms of DNA synthe-
sis, cell number (as indicated by measured amounts of DNA), cell
size (as indicated by the ratio of protein to DNA), and cell signaling
mediated by adenylyl cyclase. 
Because chlorpyrifos can cause adverse effects by allowing
acetylcholine to build up at nerve endings, the scientists tested two
receptor agonists, atropine (which blocks muscarinic receptors) and
mecamylamine (which blocks nicotinic receptors). This treatment
did not protect against the antimitotic action of chlor-
pyrifos: new cells failed to develop. However, once cells
started to differentiate, the antagonists offered some
protection against cell loss, although they could not
prevent the deterioration of adenylyl cyclase signal-
ing, which is essential for the development of neural
networks.
The second treatment, nicotine, by itself had a
small negative effect on the development of new cells, but
it protected undifferentiated cells from the actions of chlorpyrifos and
had mixed effects on cell numbers in differentiating cells. Nicotine
both stimulates and blocks nicotinic receptors, and also possesses a
mixture of pro- and antioxidant activity. The third treatment, the
antioxidant vitamin E, also protected both undifferentiated and differ-
entiating cells from many of the adverse effects of chlorpyrifos, but
worsened the deterioration of adenylyl cyclase signaling. The fourth
treatment, theophylline, a phosphodiesterase inhibitor that prevents
the breakdown of cyclic adenosine monophosphate (the second mes-
senger produced by adenylyl cyclase), was the only agent that restored
cell signaling to normal or supranormal levels but did so at further
cost to cell replication. 
This new information indicates that it might be possible to
design a cocktail of agents to counteract adverse neurodevelopmen-
tal effects of chlorpyrifos or other organophosphates, according to
the authors. But they predict that finding an appropriate mix that
avoids harmful effects inherent in the treatment agents, establishing
doses, and determining whether the cocktail works for different
chemicals will likely be a daunting task. –Rebecca Renner